Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2018-08-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
第三届监事会第十次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of resolutions passed at the 10th meeting of the 3rd Supervisory Board of 瑞康医药股份有限公司 (Realcan Pharmaceutical Co., Ltd.). It includes approvals of the 2018 semi-annual report and its summary, a special report on the use of raised funds, amendments to the company charter, and other corporate governance matters. The document is relatively short (2260 characters) and primarily reports on meeting decisions rather than containing the full semi-annual report or detailed financial statements. It also references that some reports are published elsewhere (e.g., on the cninfo website). This fits the profile of a Regulatory Filing (RNS) as it is an official regulatory announcement of meeting resolutions and approvals, not the full interim report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2018-08-23 Chinese
2018年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2018 半年度报告摘要' which translates to '2018 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, cash flow, assets, and liabilities for the half-year period of 2018. It also includes management discussion and analysis of business segments, acquisitions, disposals, and other operational details. The document is approximately 13,891 characters long, indicating it is a substantive report rather than a brief announcement. The content aligns with the characteristics of an Interim / Quarterly Report, which provides comprehensive financial statements and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is 'Interim / Quarterly Report' (IR). H1 2018
2018-08-23 Chinese
关于拟开展供应链应付账款资产证券化项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 瑞康医药股份有限公司 regarding a proposed supply chain accounts payable asset securitization project. It details the basic situation of the asset securitization, issuance scale, issuance objects, issuance period, and interest rate, as well as the need for shareholder approval and regulatory filings. The document is a formal announcement of a financing activity involving asset-backed securities issuance. It does not contain financial statements or detailed financial results but rather describes the planned financing transaction and requests shareholder authorization. The document length is 2163 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2018-08-23 Chinese
2018年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "瑞康医药股份有限公司 2018 年半年度财务报告" which translates to "Ruikang Pharmaceutical Co., Ltd. 2018 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, notes on accounting policies, and other comprehensive financial data for the half-year period ending June 30, 2018. The document explicitly states it is a half-year report and includes substantive financial data and analysis, not just an announcement or summary. It is not an earnings release or a certification letter, nor is it a regulatory announcement or a presentation. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-23 Chinese
2018年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "瑞康医药股份有限公司 2018 年半年度报告全文" which translates to "Realcan Pharmaceutical Co., Ltd. 2018 Semi-Annual Report Full Text." It explicitly states it is a half-year report for the period January 1, 2018 to June 30, 2018. The content includes detailed financial data, business overview, management discussion and analysis, and other comprehensive information typical of an interim or quarterly report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report publication or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-23 Chinese
国金证券股份有限公司关于公司使用部分闲置募集资金暂时补充流动资金事项的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Guojin Securities regarding the use of idle raised funds by Ruikang Pharmaceutical Co., Ltd. It discusses the company's use of idle raised funds to temporarily supplement working capital, including details of previous and current usage, compliance with regulatory requirements, and the opinion of the sponsor and sponsor representatives. The document references regulatory approvals, audit reports, and compliance with securities regulations. It is not a full financial report but rather a verification or audit opinion related to the use of raised funds. The document length is 2773 characters, which is relatively short and focused on a specific verification matter. This fits the category of an Audit Report / Information (AR), as it is a standalone audit/verification report on the use of funds, not a full annual or interim report, nor an announcement or presentation. FY 2018
2018-08-23 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.